| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 09/26/2002 | WO2001032156A3 Methods for treating fibroproliferative diseases |
| 09/26/2002 | WO2001019823A9 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/26/2002 | WO2000061112A3 Solubilized pharmaceutical composition for parenteral administration |
| 09/26/2002 | WO2000027868A9 Connective tissue growth factor (ctgf) and methods of use |
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137941 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137801 Administering gossypol; kits to treat patients |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137755 Tyrosine kinase inhibitors |
| 09/26/2002 | US20020137749 Formulation for menopausal women |
| 09/26/2002 | US20020137745 N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease |
| 09/26/2002 | US20020137744 Metalloprotease inhibitors |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137129 Polypeptides; genetic engineering; drug development |
| 09/26/2002 | US20020137086 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| 09/26/2002 | US20020137082 Calibration using chaperone protein |
| 09/26/2002 | US20020136784 Cyclooxygenase-2 (COX-2); administering a plant extract; nonsteroidal anti-inflammatory agents |
| 09/26/2002 | US20020136731 Targeted therapeutic delivery of vitamin D compounds |
| 09/26/2002 | US20020136724 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 09/26/2002 | DE10112771A1 New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2442268A1 Benzimidazol derivatives modulate chemokine receptors |
| 09/26/2002 | CA2441815A1 Method and composition for treatment of skeletal dysplasias |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440956A1 Oligonucleotides for regulating the gene coding for tnf.alpha. and/or genes controlled thereby and use thereof |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440623A1 Methods involving the use of capg as a diagnostic marker and methods for the identification of capg modulators for the treatment and prevention of osteoporosis and related diseasestates |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440480A1 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 09/26/2002 | CA2440261A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 09/26/2002 | CA2439539A1 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage) |
| 09/25/2002 | EP1243583A1 Heterocyclic compounds having sulfonamide groups |
| 09/25/2002 | EP1243264A2 Inhibition of nitric oxide production by retinoic acid |
| 09/25/2002 | EP1243262A1 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
| 09/25/2002 | EP1243256A1 Vaccines absorbable by the transmucosal way |
| 09/25/2002 | EP1242624A2 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 09/25/2002 | EP1242608A2 Method of achieving persistent transgene expression |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242455A1 N-alkylated peptides having antiangiogenic activity |
| 09/25/2002 | EP1242451A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 09/25/2002 | EP1242437A2 Novel stromelysin inhibitors |
| 09/25/2002 | EP1242427A1 Novel piperidine and piperazine derivatives |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242100A2 Regenerative adjuvant |
| 09/25/2002 | EP1242081A1 Caspases and apoptosis |
| 09/25/2002 | EP1242078A2 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 09/25/2002 | EP1242077A1 Novel processes for making- and a new crystalline form of- leflunomide |
| 09/25/2002 | EP1242065A1 New combination comprising a beta 2 (beta)2 adreno receptor agonist and a leukotriene receptor antagonist |
| 09/25/2002 | EP1146897B1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair |
| 09/25/2002 | EP0912184B1 Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
| 09/25/2002 | EP0702551B1 Compositions and methods for reparation and prevention of fibrotic lesions |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |
| 09/25/2002 | CN1371376A Substituted purin derivatives as inhibitors of cell adhesion |
| 09/25/2002 | CN1371372A Novel chalcones |
| 09/25/2002 | CN1371371A Novel derivatives of flavones, xanthones and coumarins |
| 09/25/2002 | CN1371370A Chalcone coumarins |
| 09/25/2002 | CN1371359A Aminobenzophenones as inhibitors IL-1 beta and TNF-alpha |
| 09/25/2002 | CN1371289A Gene therapy using TGF-beta |
| 09/25/2002 | CN1370579A Externally applied medicated wine for treating rheumarthritis |
| 09/25/2002 | CN1370571A Externally applied plaster for treating rheumatism and rheumatoid arthritis and its prepn |
| 09/25/2002 | CN1370561A Spur-eliminating medicated wine |
| 09/25/2002 | CN1370556A Medicated snake wine and its prepn |
| 09/25/2002 | CN1370537A New medicinal use and prepn process of steroid general saponin of Rhizoma Anemarrhenae as Chinese medicine |
| 09/25/2002 | CN1370526A Treating method of nuclear factor-KB mediated diseases and dysfuction |
| 09/25/2002 | CN1370523A Salmon calcitonin snuff and its prepn |
| 09/25/2002 | CN1370429A Health food |
| 09/25/2002 | CN1091446C Colchicine derivatives, use thereof and formulations containing them |
| 09/24/2002 | US6455582 Treating cancer |
| 09/24/2002 | US6455578 Aromatic derivatives and iron complexes thereof for the use as normalizing agents of the iron level |
| 09/24/2002 | US6455572 Estrogen agonist/antagonist metabolites |
| 09/24/2002 | US6455569 Connective tissue softening |
| 09/24/2002 | US6455567 Treating dermatological disorders by administering a 3-(pyrrolidin-2-ylmethyl)-5-(aminosulfonylmethyl)indole |
| 09/24/2002 | US6455562 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/24/2002 | US6455561 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase iv or tumour necrosis factor |
| 09/24/2002 | US6455529 Adhesion receptor antagonists |
| 09/24/2002 | US6455528 Tumor necrosis factor antagonist and/or interleukin promoter; antiallergens, antiinflammatory agents; autoimmune disease treatment |
| 09/24/2002 | US6455525 Heterocyclic substituted pyrazolones |
| 09/24/2002 | US6455522 Cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| 09/24/2002 | US6455520 Benzamide derivatives and their use as cytokine inhibitors |